Cyramza Approval Expanded to Include Non-Small Lung Cancer

Drug blocks blood supply that fuels tumors

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

FRIDAY, Dec. 12, 2014 (HealthDay News) -- U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small cell lung cancer (NSCLC), the agency said Friday.

NSCLC, the most common form of lung cancer, will be diagnosed in an estimated 224,000 Americans this year, and about 159,000 Americans will die from it, the FDA said, citing U.S. National Cancer Institute projections.

Cyramza is designed to block the blood supply that feeds tumors. It's intended for people whose tumors have grown during or after treatment with other drugs.

Cyramza was first approved earlier this year to treat advanced cancers of the stomach or gastrointestinal tract.

Clinical side effects have included a drop in germ-fighting white blood cells, inflammation of the mouth's lining, severe bleeding, blood clots, raised blood pressure and impaired wound healing.

Cyramza is marketed by Eli Lilly, based in Indianapolis.

More information

Visit the FDA to learn more about this approval.

--

Last Updated: